RxDoctor Payments Data

Frank Quaglieri, MD

Neurology · Reno, NVNPI 1841345766

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (58.7%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. Sanofi accounts for 86.2% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2019 at $12,992 and has fallen 98.6% since, to $181 in 2025.

$21,265in general payments, 2019–2025

Across 121 payments — averaging $175.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$18K
  • Banner Life Sciences, LLC$1K
  • Biogen$837
  • Novartis$562
  • EMD Serono, Inc.$376
  • Eisai Inc.$25
  • plus $35 from 2 others

What the payments were for

  • Consulting fees$3,07514%
  • Speaking & faculty fees$12,48759%
  • Travel & lodging$1,8969%
  • Food & beverage$3,80818%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$21,265 in reported general payments places this provider in the 80th percentile of 145 neurology providers in Nevada.

See all neurology providers in Nevada

Medicare billing

Part B allowed, 2024
$211,558
Medicare patients
361
Services billed
6,460

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RebifInterferon Beta-1a/Albumin23$225,607
CopaxoneGlatiramer Acetate24$149,759
VumerityDiroximel Fumarate17$148,783
Teriflunomide39$103,626
ProvigilModafinil14$66,449
AmpyraDalfampridine15$63,898
Glatiramer Acetate12$37,217
Dalfampridine ErDalfampridine66$14,560
Nurtec OdtRimegepant Sulfate11$12,689
Selegiline Hcl67$6,883
Carbidopa-LevodopaCarbidopa/Levodopa212$6,767
DilantinPhenytoin Sodium Extended24$6,058
Carbidopa-Levodopa ErCarbidopa/Levodopa39$5,199
Baclofen91$4,300
Levetiracetam134$3,555

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
EMD Serono, Inc.Rebif$376$225,60723 claims
BiogenVumerity$837$148,78317 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 145 neurology providers in Nevada.

Other neurology in Reno

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →